Over the past 20 years, a class of cancer drugs called CD40 agonist antibodies have shown great promise—and induced great disappointment.
This article was originally published on MedicalXpress.com
Cancer drug eliminates aggressive cancers in Phase I trial
You may also be interested in:
The Latest
PetVet Dx Revolutionizes Wildlife Conservation with AI and Molecular Diagnostics to Combat Incurable CWD in Deer and Elk
Chronic wasting disease (CWD), a devastating prion illness that affects North American cervids like deer and elk, poses a grave threat to their well-being and conservation efforts. Furthermore, it presents a potential risk of human […]
The Latest
Why you should stop buying vitamins and get more sleep instead
Almost half of all Canadians regularly take at least one nutritional supplement such as vitamins, minerals, fibre supplements, antacids and fish oils. Many of these individuals are healthy and hoping to improve general well-being or prevent chronic […]
The Latest
Will a nutritional supplement help you run better?
Whether you jog to keep fit or compete in marathons, the physically demanding sport of running can deplete the body of essential nutrients. During a race like a half-marathon, a runner’s metabolism — or ability […]
Read More:
-
If it takes a village to raise a child, it also takes a village to care for children’s food needs.This article was originally published on [...]
-
Parents are spending thousands of pounds to bank stem cells from their children’s milk teeth—but the recipient companies’ claims about their future medical value are [...]
-
Young people who are offered confidential and free access to prescription contraception methods are significantly more likely to use them, according to a new McMaster [...]
